Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

This article was originally published in PharmAsia News

Executive Summary

Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth

You may also be interested in...



Priming Russia’s Pharma Industry For Innovation

The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.

Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention

TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business

Takeda Finally Reveals €9.6B Nycomed Acquisition; Sheds Dermatology Business, But Otherwise Set On Retention

TOKYO - Takeda Pharmaceuticals Co. Ltd. finally confirmed it will acquire emerging markets player Nycomed AS. Takeda's initial denial of a $12 billion acquisition proved partially correct, instead agreeing to pay €9.6 billion ($13.7 billion) for the Swiss company, excluding its U.S dermatology business

Related Content

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel